Shanghai Henlius Biotech, Inc.

Shanghai Henlius Biotech, Inc.verified

2696.HK

Price:

$61.45

Market Cap:

$30.16B

Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a ser...[Read more]

Industry

Biotechnology

IPO Date

2019-09-25

Stock Exchange

HKSE

Ticker

2696.HK

The ROE as of December 2025 (TTM) for Shanghai Henlius Biotech, Inc. (2696.HK) is 25.67%

According to Shanghai Henlius Biotech, Inc.’s latest financial reports and current stock price. The company's current ROE is 25.67%. This represents a change of 297.19% compared to the average of 6.46% of the last 4 quarters.

Shanghai Henlius Biotech, Inc. (2696.HK) Historical ROE (quarterly & annually)

How has 2696.HK ROE performed in the past?

The mean historical ROE of Shanghai Henlius Biotech, Inc. over the last ten years is 28.04%. The current 25.67% ROE has changed -8.46% with respect to the historical average. Over the past ten years (40 quarters), 2696.HK's ROE was at its highest in in the March 2018 quarter at 89.28%. The ROE was at its lowest in in the December 2022 quarter at -21.56%.

Quarterly (TTM)
Annual

Average

28.04%

Median

-24.64%

Minimum

-42.85%

Maximum

337.89%

Shanghai Henlius Biotech, Inc. (2696.HK) ROE by Quarter and Year

Discovering the peaks and valleys of Shanghai Henlius Biotech, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 41.93%

Maximum Annual ROE = 337.89%

Minimum Annual Increase = -158.62%

Minimum Annual ROE = -42.85%

Quarterly (TTM)
Annual
YearROEChange
202427.23%9.31%
202324.91%-158.62%
2022-42.49%-0.83%
2021-42.85%37.94%
2020-31.06%41.93%
2019-21.88%-20.10%
2018-27.39%-108.11%

Shanghai Henlius Biotech, Inc. (2696.HK) Average ROE

How has 2696.HK ROE performed in the past?

The current ROE of Shanghai Henlius Biotech, Inc. (2696.HK) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

3-year avg

3.21%

5-year avg

-12.85%

10-year avg

28.04%

Shanghai Henlius Biotech, Inc. (2696.HK) ROE vs. Peers

How is 2696.HK’s ROE compared to its peers?

Shanghai Henlius Biotech, Inc.’s ROE is less than Genscript Biotech Corporation (71.23%), less than Simcere Pharmaceutical Group Limited (12.31%), greater than Shanghai Junshi Biosciences Co., Ltd. (-15.79%), less than Asymchem Laboratories (Tianjin) Co., Ltd. (6.07%), less than Livzon Pharmaceutical Group Inc. (15.39%), greater than Duality Biotherapeutics, Inc. (-469.17%), less than China Medical System Holdings Limited (9.90%), greater than Ascentage Pharma Group International (-249.24%), greater than RemeGen Co., Ltd. (-44.94%), greater than Zai Lab Limited (-27.32%),

Build a custom stock screener for Shanghai Henlius Biotech, Inc. (2696.HK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Shanghai Henlius Biotech, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Shanghai Henlius Biotech, Inc. (2696.HK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Shanghai Henlius Biotech, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Shanghai Henlius Biotech, Inc.'s ROE?

How is the ROE calculated for Shanghai Henlius Biotech, Inc. (2696.HK)?

What is the highest ROE for Shanghai Henlius Biotech, Inc. (2696.HK)?

What is the 3-year average ROE for Shanghai Henlius Biotech, Inc. (2696.HK)?

What is the 5-year average ROE for Shanghai Henlius Biotech, Inc. (2696.HK)?

How does the current ROE for Shanghai Henlius Biotech, Inc. (2696.HK) compare to its historical average?